The gene has been highlighted as a key determinant for sensitivity to the glycolytic inhibitor 2-deoxyglucose (2DG) in cancer cells, in which ARCN1 knockdown sensitized cells to 2DG. This evidence concerns the gene ARCN1 and cancer.